Skip to main content
Clinical Trials/NCT04495218
NCT04495218
Recruiting
Not Applicable

Implementation of a Next-generation Sequencing Analysis of a Panel of Genes Implicated in Incomplete Forms of Albinism

University Hospital, Bordeaux1 site in 1 country100 target enrollmentNovember 23, 2020
InterventionsBlood samples

Overview

Phase
Not Applicable
Intervention
Blood samples
Conditions
Albinism, Ocular
Sponsor
University Hospital, Bordeaux
Enrollment
100
Locations
1
Primary Endpoint
Percentage of patients for whom a molecular diagnosis is obtained based on the panel of targeted genes
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Implementation of a next-generation sequencing panel of genes to identify deleterious variants in patients with incomplete forms of albinism.

Detailed Description

Scientific context : Albinism is clinically characterised by cutaneous hypopigmentation and ophthalmologic features. These features common to all forms of albinism are foveal hypoplasia, misrouting of the optic nerves at the chiasm, retinal hypopigmentation, translucent irides and nystagmus. The molecular genetic lab at Bordeaux University Hospital is the national reference for the study of this disease. More than 1400 patients have been analyzed with a strategy including next-generation sequencing of the 19 known genes of albinism and array-CGH. Despite this thorough analysis, 25% of patients remain without molecular diagnosis. Our experience tells us that these patients often show an incomplete form of albinism with the presence of only few ophthalmologic signs. The molecular diagnosis is very challenging as the phenotype often overlaps with other ophthalmologic disorders.

Registry
clinicaltrials.gov
Start Date
November 23, 2020
End Date
June 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Bordeaux
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Minor and adult patient.
  • Patient presenting a clinical diagnosis of incomplete form of albinism with presence of at least 2 signs of ocular albinism among which nystagmus, low vision, foveal hypoplasia, retinal hypopigmentation, translucent irides, misrouting of the optic nerves at the chiasm.
  • Registered for the social security system.
  • Informed consent signed by patient or parent of a minor patient.

Exclusion Criteria

  • Refusal to participate in research protocol.

Arms & Interventions

Patient with a diagnosis of incomplete form of albinism

Intervention: Blood samples

Outcomes

Primary Outcomes

Percentage of patients for whom a molecular diagnosis is obtained based on the panel of targeted genes

Time Frame: Enrollment

the prevalence of finding at least two pathogenic variants is 10%.

Study Sites (1)

Loading locations...

Similar Trials